145 related articles for article (PubMed ID: 34859582)
1. Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti-PD-L1 Therapy.
Xiang Y; Chen L; Liu C; Yi X; Li L; Huang Y
Small; 2022 Feb; 18(6):e2104591. PubMed ID: 34859582
[TBL] [Abstract][Full Text] [Related]
2. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
4. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
5. Dissolving microneedles-based programmed delivery system for enhanced chemo-immunotherapy of melanoma.
Tian Y; Jing H; Wang Q; Hu S; Wu Z; Duan Y
J Control Release; 2023 Aug; 360():630-646. PubMed ID: 37414221
[TBL] [Abstract][Full Text] [Related]
6. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.
Chen Y; Luo X; Liu Y; Zou Y; Yang S; Liu C; Zhao Y
Int J Nanomedicine; 2022; 17():3989-4008. PubMed ID: 36105615
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Immunogenic Cell Death by Apoptosis/Ferroptosis Hybrid Pathway Potentiates PD-L1 Blockade Cancer Immunotherapy.
Jeong SD; Jung BK; Lee D; Ha J; Chang HG; Lee J; Lee S; Yun CO; Kim YC
ACS Biomater Sci Eng; 2022 Dec; 8(12):5188-5198. PubMed ID: 36449494
[TBL] [Abstract][Full Text] [Related]
8. Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade.
Li Q; Chen C; Kong J; Li L; Li J; Huang Y
Acta Pharm Sin B; 2022 May; 12(5):2533-2549. PubMed ID: 35646521
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.
Dong H; Gao M; Lu L; Gui R; Fu Y
Int J Nanomedicine; 2023; 18():3577-3593. PubMed ID: 37409026
[TBL] [Abstract][Full Text] [Related]
10. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
[TBL] [Abstract][Full Text] [Related]
11. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
[TBL] [Abstract][Full Text] [Related]
12. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
13. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.
Phung CD; Nguyen HT; Choi JY; Pham TT; Acharya S; Timilshina M; Chang JH; Kim JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
J Control Release; 2019 Dec; 315():126-138. PubMed ID: 31672625
[TBL] [Abstract][Full Text] [Related]
15. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
16. A Nanobody-Bioorthogonal Catalyst Conjugate Triggers Spatially Confined Prodrug Activation for Combinational Chemo-immunotherapy.
Zhao Z; Wang X; Wang J; Li Y; Lin W; Lu K; Chen J; Xia W; Mao ZW
J Med Chem; 2023 Sep; 66(17):11951-11964. PubMed ID: 37590921
[TBL] [Abstract][Full Text] [Related]
17. A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle.
Feng ZH; Li ZT; Zhang S; Wang JR; Li ZY; Xu MQ; Li H; Zhang SQ; Wang GX; Liao A; Zhang X
Acta Biomater; 2021 Dec; 136():495-507. PubMed ID: 34619371
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J
Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and Anti-PD-L1 Antibody Conjugated Gold Nanoparticles for Colorectal Cancer Photochemotherapy.
Emami F; Banstola A; Vatanara A; Lee S; Kim JO; Jeong JH; Yook S
Mol Pharm; 2019 Mar; 16(3):1184-1199. PubMed ID: 30698975
[TBL] [Abstract][Full Text] [Related]
20. Design of an Injectable Polypeptide Hydrogel Depot Containing the Immune Checkpoint Blocker Anti-PD-L1 and Doxorubicin to Enhance Antitumor Combination Therapy.
Shi Y; Li D; He C; Chen X
Macromol Biosci; 2021 Jun; 21(6):e2100049. PubMed ID: 33871152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
